Novel Dual-mechanism Agent Acts on Diabetes, Metabolic Complications

ADA 2019 ICYMI: Tirzepatide, a GIP and GLP-1 receptor agonist, reduces A1c and BMI as well as biomarkers of metabolic dysfunction in type 2 diabetes patients. Four studies reviewed.

Source: ConsultantLive - June 26, 2019 Category: Internal Medicine Authors: Kenneth J. Bender, PharmD, MA Tags: Diabetes Type 2 Source Type: news